SM 20220

Drug Profile

SM 20220

Alternative Names: SM-20220

Latest Information Update: 08 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class Anti-ischaemics; Neuroprotectants
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 08 Feb 2008 Discontinued - Preclinical for Neurological disorders (Prevention) in Japan (IV)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 11 Feb 2004 A preclinical study has been added to the Neurological Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top